Echinacoside attenuates post-infarction cardiac remodeling by regulating macrophage polarization and collagen deposition
Phytomedicine · 2025-11 · 148 · 157281
DOI: 10.1016/j.phymed.2025.157281 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2025-11. Verfasst von Jin Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Cardiology, The Sixth Medical Center of PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Myocardial Infarction, Glycosides, Macrophages, Ventricular Remodeling. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Inner Mongolia Medical University, Yunnan Provincial Science and Technology Department.
Abstract (Originalsprache)
BACKGROUND: Post-infarction heart failure is primarily driven by adverse ventricular remodeling, typified by macrophage-induced inflammation and excessive collagen accumulation. Echinacoside (ECH), a phenylethanol glycoside isolated from Cistanche, possesses diverse pharmacological properties; however, its cardioprotective actions remain incompletely understood. OBJECTIVE: To investigate the cardioprotective mechanisms of ECH, emphasizing its effects on macrophage polarization, collagen modulation, and molecular interactions STUDY DESIGN: A rat model of myocardial infarction (MI) was induced by ligation of the left anterior descending coronary artery, followed by a 28-day oral administration of ECH at 50 or 100 mg/kg/day. METHODS: Cardiac function was evaluated using echocardiography, while infarct size and myocardial fibrosis were analyzed through triphenyl tetrazolium chloride, Masson's trichrome, and Sirius red staining. Proteomic analysis was conducted to identify differentially expressed proteins and enriched signaling pathways. Macrophage phenotypes (M1 and M2) were characterized by immunofluorescence, quantitative real-time polymerase chain reaction, and ELISA. Molecular docking and 100-ns molecular dynamics simulations were performed to assess the binding of ECH to its targets. A pull-down assay combined with Western blotting confirmed direct interaction between ECH and Mrc1, while surface plasmon resonance was used to measure binding affinity. RESULTS: ECH significantly reduced infarct size in a dose-responsive manner (high dose: 15% vs. 38% in MI controls, p < 0.001) and improved left ventricular ejection fraction (64.7% vs. 40.3%, p < 0.05). Proteomic profiling identified 1105 proteins with altered expression; ECH reversed MI-induced upregulation of collagen type I alpha 1 and α-smooth muscle actin, and normalized macrophage polarization markers. It downregulated pro-inflammatory M1 markers (CD86, iNOS) and anti-inflammatory M2 markers (CD206, Arg1), accompanied by reduced levels of tumor necrosis factor-α interleukin-10 and interleukin-6. These effects correlated with suppression of PI3K/AKT phosphorylation, and administration of the PI3K agonist 740 YP reversed the antifibrotic actions of ECH. Computational modeling demonstrated that ECH formed stable hydrogen-bond interactions with Mrc1 (binding energy -9.9 kcal mol⁻¹) and Mrc2 (-10.0 kcal mol⁻¹), with minimal root mean square deviation (root mean square deviation < 0.1 nm) across the 100-ns simulation. Functional binding assays corroborated strong ECH-Mrc1 affinity, in agreement with the docking predictions. CONCLUSION: ECH attenuates post-MI ventricular remodeling by shifting macrophage polarization, inhibiting fibrotic signaling, and modulating PI3K-Akt activity. Its multitarget profile highlights its therapeutic relevance for ischemic heart failure, linking traditional herbal medicine with modern immunometabolic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Senior Department of Cardiology, The Sixth Medical Center of PLA General Hospital, Beijing, China.
- Department of Endocrinology, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
- Department of Vascular Surgery, Chinese PLA General Hospital, Beijing, China, Medical School of Chinese PLA, Beijing, China.
- Senior Department of Cardiology, The Sixth Medical Center of PLA General Hospital, Beijing, China; Department of Cardiology, The Third Medical Center of PLA General Hospital, Beijing, China.
- Department of Cardiology, The Third Medical Center of PLA General Hospital, Beijing, China.
- Department of Rheumatology, Inner Mongolia Autonomous Region Hospital of Traditional Chinese Medicine, Mongolia 010110, Hohhot, PR China.
Förderung
- National Key Research and Development Program of China
- Inner Mongolia Medical University
- Yunnan Provincial Science and Technology Department
- Inner Mongolia Agriculture University
- University of Science and Technology Liaoning
- Natural Science Foundation of Inner Mongolia Autonomous Region
- National Natural Science Foundation of China
- Kunming Medical University
Zitieren
APA
Zhang, J., Chen, Y., Zhou, Y., Zhu, Y., Zhao, Q., Liu, Y., Wu, X., Zhang, Y., Wang, Y., Lv, X., Zhao, Z., Tang, A., Song, Y., Xu, Y., & Zheng, C. (2025). Echinacoside attenuates post-infarction cardiac remodeling by regulating macrophage polarization and collagen deposition. Phytomedicine, 148, 157281. https://doi.org/10.1016/j.phymed.2025.157281
Vancouver
Zhang J, Chen Y, Zhou Y, Zhu Y, Zhao Q, Liu Y, et al. Echinacoside attenuates post-infarction cardiac remodeling by regulating macrophage polarization and collagen deposition. Phytomedicine. 2025;148:157281. doi:10.1016/j.phymed.2025.157281
BibTeX
@article{Zhang2025,
author = {Zhang, Jin and Chen, Yucheng and Zhou, Yujie and Zhu, Yapeng and Zhao, Qing and Liu, Ying and Wu, Xiaoxia and Zhang, Yuzhen and Wang, Yujin and Lv, Xinliang and Zhao, Ziting and Tang, Airong and Song, Yaxian and Xu, Yushan and Zheng, Chenhong},
title = {Echinacoside attenuates post-infarction cardiac remodeling by regulating macrophage polarization and collagen deposition},
journal = {Phytomedicine},
year = {2025},
volume = {148},
pages = {157281},
doi = {10.1016/j.phymed.2025.157281}
}
EUVIMED